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Abstract
Sleep-related disordered breathing (SDB) is very common in paediatric patients affected by Prader-Willi Syndrome
(PWS). However, data addressing SBD patterns and their management are lacking. The aim of the present study was
to analyse SDB features in 14 PWS patients (age range, 8 months-17 years). Polygraphic registration (PG) during a
12-h nocturnal sleep was performed in all patients. Obstructive and central apnoea indices and oxygen saturation
(SpO2) were recorded along with demographic and clinical data. Obstructive sleep apnoea (OSA) was diagnosed in
13/14 patients (92.9%); the mean obstructive apnoea-hypopnea index (OAHI) was 7.6 ± 4.2 events/h with a mean
central apnoea index (CAI) of 0.7 ± 1.04 events/h. Time spent with SpO2 < 90% was of 0.02% [range 0–23%], with
a mean oxygen desaturation index of 12.1 ± 6.9 events/h. No correlation was found between OAHI and body mass
index (mean BMI 28 ± 9.8 kg/m2 and BMI z-score 2.7 ± 1.7).
Conclusion: OSA was the predominant sleep-related disorder in our PWS patients, not associated with age or obesity, and
appeared more severe than previously reported. Further studies addressing the underlying mechanisms are necessary in larger
study populations to better design the most appropriate clinical approach.
What is Known:
• Sleep-related patterns and their management are very limited in patients with Prader-Willi syndrome.
What is New:
• Severe obstructive sleep apnoea is the most frequent sleep-related disorder in our case series.
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Abbreviation
BMI Body mass index
CAI Central apnoea index
CSA Central sleep apnoea
GH Growth hormone
OAHI Obstructive apnoea-hypopnea index
OSA Obstructive sleep apnoea
PG Polygraphic registration
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PWS Prader-Willi syndrome
SDB Sleep-disordered breathing
SpO2 Oxygen saturation
Introduction
Prader-Willi syndrome (PWS) is a multisystemic complex ge-
netic disorder caused by lack of expression of genes on the
paternally inherited chromosome 15q11.2-q13 region. It oc-
curs in 1/10000–1:30,000 live births. About two-thirds of pa-
tients (65–75%) have a de novo paternally inherited chromo-
some deletion, 20–30% havematernal uniparental disomy and
1–3% have defects in the genomic imprinting centre. PWS
infants are characterized by severe hypotonia, poor feeding
leading to failure to thrive and hypogonadism. In later infancy
and early childhood, they develop hyperphagia related to hy-
pothalamic dysfunction and, consequently, morbid obesity;
also, short stature, intellectual disabilities and behavioural
problems are parts of the clinical picture.
High prevalence of sleep-disordered breathing (SDB) is
reported among children with PWS, including obstructive
sleep apnoea (OSA), central sleep apnoea (CSA) and
hypoventilation syndromes. SDB are investigated by over-
night polygraphic registration (PG) during a 12-h night.
SDB reported in PWS children also include excessive daytime
sleepiness, altered sleep architecture, and abnormal arousal
and cardiorespiratory response to hypoxia and hypercapnia.
In addition to hypothalamic dysfunction, other factors such as
developmental brain abnormalities, craniofacial dysmorphia,
hypotonia, obesity and chest wall deformities can contribute
to the presence and severity of sleep-disordered breathing in
PWS [1].
Traditionally, OSA of PWS patients has been associated
with coexisting obesity and narrowing of the upper airways
and respiratory muscle hypotonia. Furthermore, a high num-
ber of PWS patients have CSA and associated significant ox-
ygen desaturations. CSA are reported to be more common in
PWS infants. The etiology of CSA in PWS infants seems to be
multifactorial; contributing mechanisms include hypotonia,
brainstem immaturity and hypothalamic dysfunction.
Abnormal chemosensitivity to CO2 and O2 may also contrib-
ute to hypoxia induced by respiratory depression [3].
The benefits of growth hormone (GH) therapy on improv-
ing lean muscle mass and its likely positive impact in hypo-
tonia has led to increase therapeutic use of GH in PWS infants
[4]. It is well known that PWS children have to be studied by
PG before GH therapy and then periodically, especially in the
presence of significant changes in weight, prior to and follow-
ing adenotonsillectomy and before spinal or craniofacial sur-
gery. Some authors also suggest to repeat PG 3–6 months after
start of GH therapy in PWS patients previously diagnosed and
treated for OSA [7].
The aim of this study is to describe the prevalence and
severity of SDB in a group of paediatric patients with PWS.
Materials and methods
Study population and data collection
We enrolled 14 PWS patients (genetic diagnosis correctly per-
formed; 11 males; 8 months–17 years; 6 obese) who per-
formed overnight PG between September 2014 and
November 2015. Collected data included sex, age, height
and weight at the time of the PG. It was also recorded if
patients were on GH therapy, if they had not yet started such
therapy or if they had done it in the past. Body mass index
(BMI) was calculated as weight (kg) / height (m)2. BMI z-
scores were calculated according to age- and sex-specific
growth curves of the World Health Organization [8]. Obesity
is defined as BMI > 90th percentiles (based on specific refer-
ence populations) or as BMI z-score > 2 [2].
PG All PG have been performed by trained physicians.
Patients underwent standard overnight PG using a
VitalNight (AirLiquide Medical System, Rangendigen,
Germany) data acquisition and analysis system. PG measure-
ments included chest wall and abdominal movements record-
ed by belts, nasal airflow using a nasal air pressure transducer,
oxygen saturation (SpO2) and cardiac rate. Respiratory data
included number and indices of obstructive apnoeas, obstruc-
tive hypopneas, central apnoeas and mixed apnoeas. All
events were scored according to the American Academy of
Sleep Medicine scoring guidelines [5]. Parents/caregivers
were trained to complete a sleep log to describe when subjects
fall asleep and when they are awake.
PG technical definitions:
(1) Obstructive apnoea, when airflow drops more than 90%
from baseline for at least 90% of the entire respiratory
event with chest and/or abdominal movements during
the entire event, during at least two baseline breaths;
(2) Obstructive hypopnea, when airflow drops at least 50%
from baseline during at least two baseline breaths, with
drop in SpO2 with a minimum of 3%;
(3) Central apnoea, when it happens, a complete stop of
airflow with an absence of respiratory and abdominal
effort during a minimum of 20 s or at least two baseline
breaths, with a minimum of 3% decrease of SpO2;
(4) Mixed apnoea, when airflow drops more than 90% from
baseline for at least 90% of one entire respiratory event,
during a minimum of two baseline breaths, with absent
inspiratory effort in the initial portion of the event,
followed by resumption of inspiratory effort before the
end of the event.
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PG indexes
OSA severity was graded according to accepted clinical
criteria.
Obstructive apnoea-hypopnea index (OAHI) reflects
the number of obstructive apnoeas, mixed apnoeas and
obstructive hypopneas per hour during sleep. OAHI index
of ≤ 1 events/h and CAI of ≤ 1.0 events/h have been classified
as normal PG values, OAHI > 1.5 of < 5 events/h indicated
mild OSA, OAHI > 5 of < 10 events/h indicated moderate
OSA and OAHI of ≥ 10 events/h indicated severe OSA.
Oxygen desaturation index (ODI) is the number of
desaturation events per hour. Desaturation means a drop of
basal oxyhemoglobinic saturation of at least of 3%.
Results
SDB was diagnosed in 13/14 patients (92.9%), 3 mild OSA
(21.4%), 6 moderate OSA (42.9%) and 4 severe OSA
(28.6%), while only 1 patient was negative for sleep apnoea
(7.1%). The mean OAHI was 7.6 ± 4.2/h (range 0.7–15.1/h)
while mean CAI was 0.7 ± 1.04/h (range 0–3.9/h). Three pa-
tients > 2 years old presented sporadic central events (CAI > 1
< 5) but their PG presented prevalent obstructive pattern. The
mean ODI was 12.1 ± 6.9/h (range 0.9–27/h). The median
value of mean SpO2 was 95% (range 90–99%). The mean
percentage of time spent with SpO2 < 90% was 0.02% (range
0–23%). Only one patient had nocturnal respiratory failure.
Five patients were never treated with GH, four patients were
on GH treatment and five patients have been previously
treated with GH.
It seems that GH therapy does not impact SDB, for exam-
ple, patient number 3 presents severe SDB even if treatment
with GH is ongoing since 4 years; on the other hand, patient
number 13 treated with GH in the past presents normal OAHI.
Data are presented in Table 1.
Discussion
The actual prevalence of SDB in patients with PWS is difficult
to define due to the small number of patients reported in liter-
ature, the variable selection of inclusion criteria, the wide age
ranges and the lack of multicentre studies. In the largest report
to date, including 88 adult and paediatric PWS patients follow-
ed in three Italian and French centres, Pavone et al. reported that
patients exhibited high prevalence of SDB but not associated
with obesity [6]. Cohen et al. by focusing only on 44 paediatric
PWS cases compared SDB in children over and below 2 years
of age and found that OSA was more prevalent than CSA in
patients aging > 2 years [3]. Conversely, CSA with associated
oxygen desaturations was more prevalent in < 2-year-old chil-
dren and supplemental oxygen was efficacious to treat [3].
In agreement with the previous observations [6], our study
confirms the high prevalence of SDB in PWS paediatric pa-
tients with no correlation with BMI (the Pearson test, p = 0.33)
but is in contrast with Cohen’s data which show correlation
between SDB and obesity [3]. In addition, we found that all
patients affected by SDB had a predominant obstructive
Table 1 The prevalence and severity of SDB in a group of paediatric patients
Patient
number
Age (years) Sex BMI z-score GH therapy OAHI
nv ≤ 1
CAI
nv ≤ 1
ODI Mean SpO2 T90%
nv ≤ 10
1 4.4 M 1.72 C 2.9 1.6 6.3 96% 0
2 17.5 M 2.22 P 8.4 0.2 9.7 93% 0
3 5.2 M 4.42 C 11.6 0 17.1 90% 23%
4 2.8 M 1.41 N 2.4 0.4 4.8 99% 0
5 1.7 M n.v. N 15.1 0.1 27 96% 0
6 12.7 M 5.59 P 6.7 0.6 10 95% 0
7 14.3 M 2.3 P 7.9 3.9 10.9 97% 0
8 11.2 M 0.81 C 8.4 1.4 11.4 95% 0
9 0.6 M n.v. N 12.9 0 20.3 95% 0
10 1.8 M n.v. N 6.3 0.3 16.6 96% 0
11 3.0 F 4.26 C 7.8 0 10.8 96% 0
12 5.9 F 3.12 P 11.8 0.3 17.6 93% 8%
13 17.5 M 0.69 P 0.7 0.2 0.9 97% 0
14 1.5 F n.v. N 4 0.5 6.5 96% 0
Mean ± SD 7.1 ± 6,1 2.6 ± 1,6 7.6 ± 4.2 0.6 ± 1 12.1 ± 6.9 95 ± 0.02
M male, F female, BMI body mass index, OAHI apnoea-hypopnea index, CAI central apnoea index, ODI oxygen desaturation index, SpO2 oxygen
saturation, T90% percentage of time spent with SpO2 < 90%, n.v. not valid, C on course, P in the past, N never, nv normal values
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respiratory pattern, according to Pavone et al. [6], without age-
related differences. Our study population also exhibited a
more severe sleep disorders. In contrast, mean OAHI was of
9.6 ± 5.27 among patients, < 2 years old, and 6.86 ± 3.76
among those aging > 2 years. Similarly, mean ODI values
were 17.6 ± 8.6 in patients, < 2 years old, and 9.95 ± 5.11 in
patients aging > 2 years. Conversely, both OAHI and ODI
values were reported to be lower in previous literature obser-
vations [3, 6]. To date, unlike Pavone et al. that showed an
increasing OAHI from childhood to adulthood [6], mean
OAHI higher were higher in patients aging ≤ 2 years in our
case series. Finally, we did not find considerable CAI events in
agreement with Pavone’s data [6] while Cohen et al. described
a relevant CAI phenomenon significantly correlated with low
age (less than 2 years) [3].
Conversely to Pavone and Cohen, our study involved both
patients already in GH therapy and patients GH treatment-
naïve. We did not find any correlation between GH therapy
and sleep respiratory disorders but the limited number of cases
could be a limitation about this data.
Our study has several limitations. First, the number of cases
are limited and the age range is very wide. Second, we did not
have polysomnographic recordings so we are not able to stage
accurately sleep stage and hypopneas linked to arousal. Third,
we had information about sleep quality only thanks to sleep
log completed by parents/caregivers as well as information on
the prevalence of nocturnal hypoventilation were not available.
In conclusion, OSA is the predominant sleep-related disor-
der in our PWS patient with the lack of association with obe-
sity suggesting that hypotonia and/or facial dysmorphic fea-
tures might play a pivotal role in SDB. As up to now, there are
still few available data addressing the mechanisms of SDB in
PWS patients; further data are necessary in larger study pop-
ulations to better define clinical and instrumental features of
SDB in PWS patients and to find the most appropriate therapy
and follow-up strategies.
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